Two things happened as the trial progressed
1. The more patients that were recruited, treated and the results analysed, the closer the results got to the true outcome and the true effect of the treatment under study
2. The more patients that were treated, the fewer patients remained that could potentially alter the outcome
Chance may have allowed the result to remain in doubt at the 30% and 45% interim analyses.
Novartis deal on the rocks, page-113
-
- There are more pages in this discussion • 135 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $5.512M | 4.688M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 57 | 74920 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 61136 | 14 |
View Market Depth
| Last trade - 15.48pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |